Clinical Trials Directory

Trials / Completed

CompletedNCT04709718

Surgical Management of Giant Hepatic Hemangioma

Surgical Management of Giant Hepatic Hemangioma: a 10-year Single Center Experience

Status
Completed
Phase
Study type
Observational
Enrollment
12 (actual)
Sponsor
Université de Sousse · Academic / Other
Sex
All
Age
15 Years – 90 Years
Healthy volunteers

Summary

Hepatic hemangiomas are the commonest benign mesenchymal lesions of the liver. Most of these lesions are asymptomatic. Giant hepatic hemangiomas (GHH) (\> 10 cm) are often symptomatic and require surgical intervention. This study aimed to describe the clinical findings, risk factors, diagnostic approach and management of GHH.

Detailed description

Hepatic hemangiomas are the most common benign tumors of the liver with the incidence of 0.4 to 20% . They are most often discovered incidentally on imaging studies. Typical hemangiomas usually do not increase in size over time and therefore are unlikely to cause symptoms. Giant hepatic hemangiomas (GHH) are defined as hemangiomas larger than 5 cm . They are usually responsible for overt clinical symptoms and complications consisting, most often, of upper abdominal pain, hemorrhage, biliary compression, or a consumptive coagulopathy that may require prompt surgical intervention or other treatments . Management of liver hemangiomas ranges from close observation to surgery depending upon the site, size and symptoms . It is widely accepted that intervention is indicated only for symptomatic hemangiomas. Surgical resection is indicated in patients with abdominal complaints or complications, or when diagnosis remains inconclusive. The ideal surgical treatment for GHH is still controversial. Enucleation is the preferred surgical method based on the existing literature. In this study, we report our 17-year experience of clinical management of GHH.

Conditions

Interventions

TypeNameDescription
PROCEDUREhepatectomyliver resection taking over the liver hemangioma

Timeline

Start date
2008-01-01
Primary completion
2019-06-29
Completion
2020-01-02
First posted
2021-01-14
Last updated
2021-01-14

Source: ClinicalTrials.gov record NCT04709718. Inclusion in this directory is not an endorsement.